通关藤注射液联合GC方案治疗晚期NSCLC的效果及对外周血T淋巴细胞亚群的影响

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (555 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

[Abstract] Objective To investigate the efficacy of Tongguanteng Injection combined with GC regimen in the treatment of advanced non-small cell lung cancer (NSCLC) and its influence on peripheral blood T lymphocyte subsets. Methods Seventy patients with NSCLC treated in the Department of Oncology, Guang’anmen Hospital Southern District, China Academy of Traditional Chinese Medicine from March 2020 to March 2021 were selected and they were divided into control group and study group according to the random number table method, with 35 patients in each group. The control group was treated with GC alone, and the study group was treated with GC + Tongtengteng Injection. The adverse reactions of the two groups were recorded, the short-term efficacy was evaluated, and the changes of T lymphocyte subsets and quality of life were observed. Results The short-term efficacy of the study group was better than the control group, and the objective remission rate was higher than the control group, the differences were statistically significant (P ＜ 0.05). There was no significant difference in disease control rate between the two groups (P ＞ 0.05). After two cycles of treatment, the proportion of CD3+, CD4+ and CD4+/CD8+ in both groups increased, and those in the study group were higher than the control group, and the proportion of CD8+ was decreased, and the study group was lower than the control group, the differences were statistically significant (P ＜ 0.05). After two cycles of treatment, KPS score of both groups increased and the study group was higher than the control group, the differences were statistically significant (P ＜ 0.05). Compared with the control group, the incidence of grade Ⅲ-Ⅳ nausea and vomiting and grade Ⅲ-Ⅳ leukopenia was significantly decreased in the study group, while the incidence of grade Ⅰ-Ⅱ leukopenia was increased, and the differences were statistically significant (P ＜ 0.05). Conclusion Tongguanteng Injection and combined GC regimen in the treatment of advanced NSCLC can achieve better short-term efficacy, improve the distribution of T lymphatic subgroups, promote the recovery of immune function, reduce the side effects of chemotherapy, and improve the quality of life of patients, which is worthy of clinical reference.

Key words： Tongguanteng Injection GC chemotherapy regimen Advanced lung cancer T lymphocyte subsets Side effects

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIU Junqing1 LI Liang2 LIU Rui3

Cite this article:

XIU Junqing1 LI Liang2 LIU Rui3. Efficacy of Tongguanteng Injection combined with GC regimen in the treatment of advanced NSCLC and its influence on peripheral blood T lymphocyte subsets[J]. 中国医药导报, 2022, 19(14): 101-104.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I14/101

[1] SungH，Ferlay J，Siegel RL，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] 孟春柳，徐利明，魏佳，等.晚期小细胞肺癌和非小细胞肺癌不同转移部位预后意义的比较[J].中国肿瘤临床，2019，46（21）：23-28.
[3] Grieshober L，Graw S，Barnett MJ，et al. AHRR methylation in heavy smokers：Associations with smoking，lung cancer risk，and lung cancer mortality [J]. BMC Cancer，2020，20（1）：905.
[4] 朱丽娜，武文辉，钟敏，等.消癌平联合吉非替尼对进展期非小细胞肺癌患者凝血功能及临床疗效的影响[J].实用癌症杂志，2020，35（1）：77-81.
[5] 徐媛媛，陶宋词，胡世莲，等.中药复方联合常规治疗对恶性肿瘤化疗期间骨髓抑制及细胞因子的影响[J].中国临床保健杂志，2019，22（3）：349-352.
[6] Yang S，Che H，Xiao L，et al. Traditional Chinese medicine on treating myelosuppression after chemotherapy：A protocol for systematic review and meta-analysis [J]. Medicine，2021，100（4）：1097-1107.
[7] 张梦迪，牟睿宇，刘宏根，等.消癌平注射液联合化疗治疗晚期非小细胞肺癌的Meta分析[J].天津中医药，2019， 36（5）：466-473.
[8] 李娟娟，张云，韩利文，等.消癌平药理作用与不良反应研究进展[J].现代医药卫生，2017，33（2）：223-225.
[9] 葛亚楠，张冠中，刘兆喆，等.消癌平注射液联合替吉奥胶囊治疗老年晚期胃癌的临床疗效及不良反应观察[J].肿瘤药学，2019，9（6）：892-896.
[10] Markussen A，Jensen LH，Diness LV，et al. Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin，Gemcitabine，and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase Ⅱ Trial [J]. Cancers，2020，12（7）：1975-1985.
[11] 熊万成，郗玉玲，平贯芳，等.lncRNA PVT1在结直肠癌组织和细胞中的表达及其对顺铂化疗敏感性的影响及机制[J].中国肿瘤生物治疗杂志，2019，26（7）：743-750.
[12] 高宇，林彦馨，杨跃辉.吉西他滨联合顺铂或卡铂治疗非小细胞肺癌的临床疗效及安全性分析[J].中国临床药理学杂志，2019，35（19）：2430-2434.
[13] 葛亚楠，刘兆喆，张冠中，等.消癌平注射液治疗结直肠癌患者真实世界临床应用特征研究[J].肿瘤药学，2021， 11（2）：207-210.
[14] 阮新建，贾佳，刘慧龙，等.消癌平注射液联合SOX化疗方案一线治疗晚期胃癌的临床观察[J].临床合理用药，2021，14（8）：13-16.
[15] 王铁山，尚培中，王华，等.消癌平注射液联合TE方案治疗晚期乳腺癌的临床评价[J].河北北方学院学报：自然科学版，2019，35（2）：12-14.
[16] 王惠枫，沈静，张甜甜.消癌平片联合常规化疗对胃癌患者血清TGF-α，VEGF水平的影响[J].海南医学，2020， 31（2）：51-53.
[17] 中华医学会肿瘤学分会，中华医学会杂志社.中华医学会肿瘤学分会肺癌临床诊疗指南（2021版）[J].中华肿瘤杂志，2021，43（6）：591-621.
[18] 孙燕，周际昌.临床肿瘤内科手册[M].3版.北京：人民卫生出版社，1996：53-54.
[19] Therasse P，Arbuck SG，Eisenhauer EA，et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors [J]. Bull Cancer，2000，87（12）：881-886.
[20] 万德森.临床肿瘤学[M].4版.北京：科学出版社，2019：240-243.
[21] Xsa B，Zl C，Jian SD，et al. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab [J]. Lung Cancer，2021， 154（6）：105-112.
[22] 何青红，史和平.消癌平注射液辅助肝动脉化疗栓塞术治疗肝细胞肝癌患者的临床疗效研究[J].实用癌症杂志，2019，34（12）：2014-2016，2023.
[23] 陈玉，李强，张聪，等.消癌平注射液辅助TP方案化疗对晚期NSCLC患者免疫状态，不良反应及生命质量的影响[J].国际肿瘤学杂志，2019，46（1）：17-21.
[24] 胡彦辉，崔庆丽，马东阳，等.消癌平注射液对非小细胞肺癌患者T淋巴细胞亚群的影响[J].中国临床医生，2019， 47（5）：570-573.
[25] 李媛媛，吉海杰，贺石麟，等.通关藤总皂苷对人肝癌HepG2细胞增殖抑制作用的研究[J].肿瘤研究与临床，2019，31（2）：73-77.
[26] 罗劼妍，黄浩，黄胜兰，等.肺癌患者外周血淋巴细胞亚群水平的表达及临床意义[J].现代生物医学进展，2018， 18（2）：326-329.
[27] 周进，罗宏，林征，等.晚期肺癌患者靶向治疗后外周血T淋巴细胞亚群表达变化及临床意义[J].中国当代医药，2021，28（20）：109-111.